Compare Recursion Pharmaceuticals Inc (RXRX) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Warner Music Group Corp — how do they compare? Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B), while Warner Music Group Corp trades at $28.16 (market cap $14.66B). The key difference: Warner Music Group Corp is far larger — about 7.9× Recursion Pharmaceuticals Inc's market cap, and Warner Music Group Corp pays a 2.85% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | WMG | |
|---|---|---|
Market Cap | $1.86B | $14.66B |
Sector | Health | Media |
52-Week High | $6.79 | $34.72 |
52-Week Low | $2.84 | $23.65 |
Enterprise Value | $1.38B | $18.96B |
Dividend Yield | — | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Warner Music Group (WMG) trades at $28.03, down 2.61% on the day, with a bearish technical signal. Recent earnings show mixed quarterly beats, with Q1 and Q2 2026 exceeding expectations but Q4 2025 missing. Revenue has grown steadily from $5.9B in 2022 to $6.7B in 2025, though net income margin declined to 5.44%. The company maintains a strong ROE of 25.38% and recently announced a strategic AI music partnership with Suno (Reuters, 2026-09-09).
Outlook is cautiously optimistic with analyst consensus at 66.7% buy ratings. Key opportunities include streaming growth and AI initiatives, while risks involve margin pressure and leadership changes. The stock's valuation at a P/E of 22.42 appears reasonable given growth prospects, but investors should monitor execution on margin improvement and competitive dynamics in the music industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
